Genentech: Press Releases | Friday, Sep 13, 2024
WEB6 days ago · Ocrevus Zunovo™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs. South San Francisco, CA -- September 13, 2024 --. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus ...
Roche scores with FDA nod for subcutaneous version of MS star Ocrevus
WEB6 days ago · Ocrevus is currently Roche’s top-selling product, with 2023 sales reaching 6.38 billion Swiss francs ($7 billion), which was good for 13% growth over 2022 at constant exchange rates.
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze …
WEB3 days ago · ROG.SW. HALO. Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics ...
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, …
WEB2 days ago · FDA approves Ocrevus Zunovo as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis. News release. Genentech.
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates …
WEBApr 17, 2024 · Ocrevus is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support)...
ECTRIMS 2023: New under-the-skin Ocrevus found effective in MS
WEBOct 12, 2023 · by Marisa Wexler, MS October 12, 2023. A new under-the-skin formulation of Ocrevus (ocrelizumab) — administered in 10 minutes — is at least as effective as the approved intravenous, or...
FDA approves new drug to treat multiple sclerosis | FDA
WEBOn March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple...
Positive Results Announced from Phase 3 OCARINA II Trial …
WEBJul 13, 2023 · OCARINA II is a global Phase III multicentre, randomised study evaluating the pharmacokinetics, safety and radiological and clinical effects of the subcutaneous formulation of OCREVUS compared ...
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) …
WEBJul 13, 2023 · Ocrevus is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and...
AAN 2024: Subcutaneous Ocrevus shows benefits after 1 year
WEBApr 23, 2024 · A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according...